You are here
Imaging multiple sclerosis
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and researchThe Lancet Neurology, Volume 13, Issue 9, September 2014, Pages 936–948
Robert A. Brown, Sridar Narayanan, Douglas L. Arnold
NeuroImage: Clinical, pages 20 - 25
Amir-Hadi Maghzi, Nisha Revirajan, Laura J. Julian, Rebecca Spain, Ellen M Mowry, Shuang Liu, Chengshi Jin, Ari J. Green, Charles E. McCulloch, Daniel Pelletier, Emmanuelle Waubant
Multiple Sclerosis and Related Disorders
Martin Weygandt, Hannah-Maria Hummel, Katharina Schregel, Kerstin Ritter, Carsten Allefeld, Esther Dommes, Peter Huppke, JohnDylan Haynes, Jens Würfel, Jutta Gärtner
- The Lancet Neurology, Volume 13, Issue 8, August 2014, Pages 807–822
D. Seixas, P. Foley, J. Palace, D. Lima, I. Ramos, I. Tracey
Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophyJournal of Neuroimmunology, Available online 26 June 2014
- Journal of Clinical Neuroscience, Available online 11 July 2014
From Dr. Claire Riley: The shrinking diagnostic category of clinically isolated syndrome is reviewed in detail by Professors Miller and Brownlee, contextualizing the shift in diagnostic criteria in 2010. The differences in prescribing practices in the UK and US are highlighted. The authors describe the need for accurate biomarkers in order to distinguish among CIS patients, and identify which patients would most benefit from treatment with disease modifying therapy. As pressure on health care spending increases, these biomarkers may become critical in determining which patients merit treatment. MRI metrics such as deep grey matter atrophy or cortical lesions may prove valuable in identifying those CIS patients likely to go on to develop disability from the disease.
Therapeutic strategies in multiple sclerosis: A focus on neuroprotection and repair and relevance to schizophreniaSchizophrenia Research, Available online 2 June 2014
Matilde Inglese and Maria Petracca provide a thoughtful review of the currently available disease modifying agents for relapsing MS and their potential neuroprotective effects and implications for progressive MS, in their review “Therapeutic strategies in multiple sclerosis: A focus on neuroprotection and repair and relevance to schizophrenia.” The authors review the advanced MR imaging techniques of both gray and white matter that may support neuroprotective effects in these agents or other investigational agents. Drawing a parallel with the inflammatory and neurodegenerative features of schizophrenia, the authors highlight potential application of work done in MS to the field of schizophrenia, and vice versa. As the options for treatment of relapsing MS become more varied, our focus on progressive MS must sharpen, including the analysis of existing agents for potential neuroprotective effects, as described here.
- Journal of the Neurological Sciences, Volume 342, Issues 1–2, 15 July 2014, Pages 62–68